WO1996015245A1 - Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique - Google Patents
Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique Download PDFInfo
- Publication number
- WO1996015245A1 WO1996015245A1 PCT/US1995/015191 US9515191W WO9615245A1 WO 1996015245 A1 WO1996015245 A1 WO 1996015245A1 US 9515191 W US9515191 W US 9515191W WO 9615245 A1 WO9615245 A1 WO 9615245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- smooth muscle
- cell cycle
- expression
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 35
- 230000001575 pathological effect Effects 0.000 title claims abstract description 22
- 230000001613 neoplastic effect Effects 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims description 60
- 230000008569 process Effects 0.000 title claims description 45
- 230000002401 inhibitory effect Effects 0.000 title claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 82
- 210000001367 artery Anatomy 0.000 claims abstract description 36
- 239000013604 expression vector Substances 0.000 claims abstract description 23
- 101710150974 Regulator of chromosome condensation Proteins 0.000 claims abstract description 18
- 102100039977 Regulator of chromosome condensation Human genes 0.000 claims abstract description 18
- 230000002062 proliferating effect Effects 0.000 claims abstract description 17
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 12
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 12
- 239000002157 polynucleotide Substances 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 136
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 76
- 230000014509 gene expression Effects 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 48
- 208000037803 restenosis Diseases 0.000 claims description 41
- 230000035755 proliferation Effects 0.000 claims description 35
- 238000002399 angioplasty Methods 0.000 claims description 26
- 238000001727 in vivo Methods 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 206010003162 Arterial injury Diseases 0.000 claims description 9
- 210000002464 muscle smooth vascular Anatomy 0.000 claims description 9
- 210000004351 coronary vessel Anatomy 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 210000002460 smooth muscle Anatomy 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 206010051589 Large intestine polyp Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 210000004922 colonic epithelial cell Anatomy 0.000 claims description 2
- 210000001608 connective tissue cell Anatomy 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 230000001329 hyperkeratotic effect Effects 0.000 claims description 2
- 208000011379 keloid formation Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- 210000000064 prostate epithelial cell Anatomy 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 210000004920 epithelial cell of skin Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 238000012546 transfer Methods 0.000 abstract description 24
- 241000701161 unidentified adenovirus Species 0.000 description 77
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 59
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 59
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 59
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 59
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 59
- 208000015181 infectious disease Diseases 0.000 description 44
- 241000700159 Rattus Species 0.000 description 39
- 230000000694 effects Effects 0.000 description 28
- 241000700605 Viruses Species 0.000 description 25
- 210000001715 carotid artery Anatomy 0.000 description 23
- 230000000638 stimulation Effects 0.000 description 23
- 108091026890 Coding region Proteins 0.000 description 21
- 230000001404 mediated effect Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 108050006400 Cyclin Proteins 0.000 description 19
- 230000022131 cell cycle Effects 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 230000006378 damage Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 208000014674 injury Diseases 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 230000006369 cell cycle progression Effects 0.000 description 17
- 230000002018 overexpression Effects 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 14
- 239000012894 fetal calf serum Substances 0.000 description 14
- 238000001415 gene therapy Methods 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 108091007914 CDKs Proteins 0.000 description 13
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000003119 immunoblot Methods 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 108010005774 beta-Galactosidase Proteins 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 239000013592 cell lysate Substances 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 208000034827 Neointima Diseases 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000000824 cytostatic agent Substances 0.000 description 8
- 101150066555 lacZ gene Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000018199 S phase Effects 0.000 description 7
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 230000001085 cytostatic effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 6
- 208000010370 Adenoviridae Infections Diseases 0.000 description 6
- 206010060931 Adenovirus infection Diseases 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 102000016736 Cyclin Human genes 0.000 description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000003910 Cyclin D Human genes 0.000 description 5
- 108090000259 Cyclin D Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000009456 molecular mechanism Effects 0.000 description 5
- 230000008692 neointimal formation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 230000002463 transducing effect Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 108700009124 Transcription Initiation Site Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- 102000049765 human CDKN1A Human genes 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012342 propidium iodide staining Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- IPDRTIBDOPMMIQ-VAOFZXAKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C)O[C@H](CO)[C@@H](O)C1 IPDRTIBDOPMMIQ-VAOFZXAKSA-N 0.000 description 2
- NDJNDUULNXNRQD-XKBRQERYSA-N 1-[(2r,4s,5s)-5-[bromo(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](C(Br)O)O[C@H]1N1C(=O)NC(=O)C=C1 NDJNDUULNXNRQD-XKBRQERYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000010867 Carotid Artery injury Diseases 0.000 description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 2
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 230000008051 G1/S transition checkpoint Effects 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 206010024774 Localised infection Diseases 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 2
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 2
- 108091006313 SLC3A2 Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000313 clinical toxicology Toxicity 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000003748 coronary sinus Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000944683 Bandara Species 0.000 description 1
- 238000012756 BrdU staining Methods 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101100351187 Mus musculus Pcna gene Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101000742868 Rattus norvegicus Retinoblastoma-associated protein Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010062910 Vascular infections Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 235000020289 caffè mocha Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- YDMCWONVABEGBK-UHFFFAOYSA-N carbamimidoylazanium;phenoxide Chemical compound NC(N)=N.OC1=CC=CC=C1 YDMCWONVABEGBK-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 229940000207 selenious acid Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Definitions
- the present invention relates to a process of inhibiting non- neoplastic pathological cell proliferation in a cell in vivo.
- a process of the present invention involves transducing a cell with an eukaryotic expression vector comprising a polynucleotide that encodes a dominant-negative cell cycle regulatory protein.
- Somatic gene therapy can be defined as the ability to program the expression of foreign genes in non-germ line (i.e., non-sperm and egg) cells of an animal.
- Methods of somatic gene therapy can be divided into two categories, ex vivo gene therapy involving the removal of cells from a host organism, transfection of a foreign gene into those cells, and re-implantation or transplantation of the transformed or transgenic cells back into a recipient host.
- ex vivo gene therapy involves transfection of a foreign gene directly into cells of a recipient host without the need for prior removal of those cells from the host.
- somatic gene therapy for human subjects is dependent upon a number of factors.
- Several possible strategies to introduce genes into tissues of the body have been employed in the past (Stratford-Perricaudet et al.. 1990; Rosenfeld et al.. 1992; Wolfe et al.. 1992). Procedures to introduce foreign genes into cells include direct transfection (Davis et al. 1986) and retroviral gene transfer (Dichek et al.. 1991: Wilson et al..
- adenovirus-mediated gene transfer has been investigated as a means of somatic gene therapy into eukaryotic cells and into whole animals (van Doren et al.. 1984a; van Doren et al.. 1984b; Ghosh-Choudhury and Graham. 1987: Stratford-Perricaudet et 3 , 1990: Rosenfeld et al.. 1991: Rosenfeld et al.. 1992).
- a problem with adenovirus mediated gene transfer is the low level of gene product expression in target cells and a resultant lack of a functional effect.
- adenovirus-mediated gene transfer has been used to treat ornithine transcarbamylase (OTC) deficiency in newborn mice
- OTC ornithine transcarbamylase
- the expression of the ornithine transcarbamylase enzyme in the virus infected mice was typically at or below expression levels in normal mice with the result that the defect was only partially corrected (Stratford-Perricaudet et al.. 1990).
- adenovirus-mediated gene transfer would be applicable to treatment of a disease requiring an overexpression of a gene product.
- adenovirus mediated transfer of the gene for cystic fibrosis transmembrane conductance regulator (CFTR) into the pulmonary epithelium of cotton rats has been attempted, although it has not been possible to assess the biological activity of the transferred gene because there was no physiologic effect of gene transfer despite expression of the CFTR protein in lung airway cells (Rosenfeld et al.. 1992). Still further, lung expression of 1-antitrypsin protein was not associated with a physiologic effect ( Rosenfeld et al.. 1991). Taken together, those data do not demonstrate that adenovirus can transfer genes into cells and direct the expression of sufficient protein to achieve a physiologically relevant effect.
- CFTR cystic fibrosis transmembrane conductance regulator
- Somatic gene therapy can be used in the treatment of a number of pathological conditions characterized by unregulated or pathological cellular proliferation.
- Somatic gene therapy can also be used to directly study the molecular mechanisms regulating abnormal or pathological cell proliferation such as occurs in metastatic cancer cells or in injured vascular smooth muscle cells.
- the present invention provides a process of inhibiting non- neoplastic pathological cellular proliferation in a cell in vivo.
- the process comprises transducing the cell with an eukaryotic expression vector including a polynucleotide that encodes an inhibitory cell cycle regulatory protein.
- the vector drives expression of the polynucleotide in the cell.
- the expression vector is replication-defective adenovirus type 5.
- the adenovirus lacks the early gene region E1 or the early gene regions E1 and E3.
- the cell whose proliferation is being inhibited is a vascular smooth muscle cell.
- transducing is accomplished by infusing the expression vector into an artery that contains the vascular smooth muscle cell.
- the inhibitory cell cycle regulatory protein is p53 or p21. In another embodiment, the inhibitory protein is a dominant-negative cell cycle regulatory protein such as a non- phosphorilatable form of Rb-1.
- the expression vector preferably further includes an enhancer-promoter other than an adenovirus enhancer- promoter, where the enhancer-promoter's operatively linked to the polynucleotide that encodes the regulatory protein.
- the enhancer-promoter includes the CMV promoter, an SV40 early promoter, a RSV promoter, the elongation factor promoter (EF1 ⁇ ), or a MCK enhancer or 4 ⁇ 2 heavy chain.
- the enhancer-promoter is specific for vascular smooth muscle such as an endothelin promoter or a smooth muscle -actin promoter.
- the present invention provides a process of inhibiting pathological proliferation of vascular smooth muscle cells.
- the process includes the step of increasing the level of p21 in the cells.
- the level of p21 is increased by increasing the expression of p21 in the cells.
- p21 expression is increased by transforming those cells with an expression vector that contains a polynucleotide that encodes p21 operatively linked to a promoter that drives expression of p21 in the cell.
- a preferred expression vector is a replication-defective adenoviral vector.
- An especially preferred adenoviral vector is designated Adp21.
- the expression of p21 in vascular smooth muscle cells can be increased in those cells either in vivo or in vitro. Where the cells are located in vivo, cells can be transformed with a suitable expression vector using direct in vivo or ex vivo transformation procedures.
- the expression vector is injected into a blood vessel containing the cell. Intraarterial injection is preferred.
- a process of the present invention can be used to inhibit any pathological proliferation of vascular smooth muscle cells.
- the process is used to inhibit the pathological proliferation following arterial injury or during restenosis.
- the present invention provides a process of treating a vascular proliferative disorder in an animal in need of such treatment comprising administering to the animal an effective amount of an expression vector that contains a polynucleotide that encodes p21 operatively linked to a promoter that drives expression of p21 in vascular smooth muscle.
- the present invention addresses one or more shortcomings in the prior art through the provision of a process for inhibiting non- neoplastic pathological cell proliferation without necessarily causing cell death.
- an eukaryotic expression vector construct is used to deliver a gene to the proliferating cell and thus affect expression of that gene's product.
- the gene product is a dominant-negative cell cycle regulatory protein. Expression of the gene product thereby alters function of those cells and inhibits the pathological proliferation.
- a process of the present invention can be used to inhibit proliferation of a cell situated in vivo in a living organism.
- the present invention provides a process of inhibiting non- neoplastic pathological cellular proliferation in a cell in vivo, the process comprising transducing the cell with an eukaryotic expression vector comprising a polynucleotide that encodes an inhibitory cell cycle regulatory protein, the vector driving expression of the polynucleotide in the cell.
- non-neoplastic pathological cellular proliferation means unregulated, uncontrolled or abnormally controlled cell proliferation. That phrase is meant to incorporate all non-neoplastic types of cellular proliferation other than the normal or physiological type of proliferation that a particular cell type undergoes.
- Exemplary non-neoplastic pathological cellular proliferations are fibroblast proliferation in keloid formation after surgery, prostate epithelial cell proliferation in benign prostatic hypertrophy, uterine smooth muscle and fibroblast proliferation in uterine fibroids, colonic epithelial and connective tissue cell proliferation in benign colonic polyps, benign neuromas, skin epithelial cell proliferation in hyperkeratotic skin diseases and vascular smooth muscle proliferation following vascular injury.
- Exemplary vascular injuries are restenosis following balloon angioplasty of coronary arteries, restenosis following balloon angioplasty of peripheral arteries (e.g., renal, femorals, carotids), restenosis following stenting of the coronary arteries, coronary artery bypass graft restenosis and occlusion, peripheral artery bypass graft stenosis, restenosis of arterial-venous shunts in renal dialysis patients, primary pulmonary hypertension, accelerated atherosclerosis following heart transplantation and glomeruloproliferative disorders.
- peripheral arteries e.g., renal, femorals, carotids
- a process of the present invention is used to inhibit vascular smooth muscle proliferation during restenosis.
- a preferred cell therefore, is a vascular smooth muscle cell.
- the arterial wall is a complex multicellular structure that plays important roles in inflammation, coagulation, and the regulation of blood flow.
- Vascular smooth muscle cells are located predominantly in the arterial tunica media and are important regulators of vascular tone and blood pressure. These cells are normally maintained in a non- proliferative state in vivo.
- Arterial injury results in the migration of vascular smooth muscle cells into the intimal layer of the arterial wall where they proliferate and elaborate extracellular matrix components. This neointimal smooth muscle cell proliferative response has been implicated as important in the pathogenesis of atherosclerosis (Forrester et al., i99i; Ji2_eLa 1990). Page missing at the time of publication
- p21 also known as Cip 1 (CDK- interacting protein), Sdi1 (senescent cell-derived inhibitor), and WAF1 (wild-type p53-activated fragment)
- Cip 1 CDK- interacting protein
- Sdi1 senescent cell-derived inhibitor
- WAF1 wild-type p53-activated fragment
- p21 monomers can associate with active cyclin D/CDK complexes in proliferating fibroblasts
- over-expression of p21 in such fibroblasts has been shown to potently inhibit the in vitro kinase activity of these cyclin/CDK complexes and to arrest these cells in the G1 phase of the cell cycle.
- p21 may inhibit cell cycle progression by inhibiting the cyclin D/CDK dependent phosphorylation of Rb.
- this effect has not been demonstrated directly in mammalian cells.
- p21 In addition to its ability to inhibit the kinase activities of cyclin/CDK complexes, p21 has also been reported to bind to and inhibit the activity of the DNA polymerase oc co-factor, PCNA. Recent studies have suggested that different regions of the p21 protein are required for its CDK and PCNA inhibitory activities. Thus, p21 appears to inhibit cell cycle progression by at least two independent molecular mechanisms.
- adenovirus-mediated over- expression of p21 inhibits VSMC proliferation in response to serum stimulation in vitro. This effect is associated with a complete inhibition of Rb phosphorylation and with the formation of p21/PCNA complexes in the cells programmed to overexpress p21.
- Localized infection of the arterial wall at the time of balloon angioplasty with a replication- defective adenovirus encoding p21 markedly inhibited restenosis in the rat carotid artery model of vascular injury.
- Eukaryotic expression vectors are well known in the art ( Sambrook et al.. 1989).
- a preferred expression vector construct is an adenovirus vector construct.
- the use of adenovirus as a vector for cell transfection is well known in the art.
- Adenovirus vector-mediated cell transfection has been reported for various cells (Stratford-Perricaudet. et al.. 1992).
- An adenovirus vector of the present invention is replication defective.
- a virus is rendered replication defective by deletion of the viral early gene region 1 (E1).
- An adenovirus lacking an E1 region is competent to replicate only in cells, such as human 293 cells, which express adenovirus early gene region 1 genes from their cellular genome.
- an adenovirus vector used in the present invention is lacking both the E1 and the E3 early gene regions. Techniques for preparing replication defective adenoviruses are well known in the art (See, e.g. McGrorv et a , 1988, and Guzman et al.. 1982).
- an adenovirus vector can be of any of the 42 different known serotypes or subgroups A-F.
- Adenovirus type 5 of subgroup C is the preferred starting material for production of a replication-defective adenovirus vector.
- An adenovirus is engineered to contain a coding DNA sequence for use as a vector.
- a recombinant adenovirus has been described by Gluzman et al., 1982.
- Individual DNA sequences such as cDNAs that encode a gene product are inserted into the adenovirus to create a vector construct.
- a coding sequence for a gene product is introduced or incorporated into an adenovirus at the position from which the E1 coding sequences have been removed.
- the position of insertion within the adenovirus sequences is not critical to the present invention.
- a coding sequence can also be inserted in lieu of the deleted E3 region in E3 replacement vectors as described previously by Karlsson et al. (1986).
- the E1 region of adenovirus is replaced by the coding DNA sequence or gene.
- the resulting adenovirus vector is co-transfected into 293 cells together with a plasmid carrying a complete adenovirus genome to propagate the adenovirus.
- An exemplary such plasmid is pJM17.
- Co- transfection is performed in accordance with standard procedures well known in the art.
- 293 cells are cultured in Dulbecco's modified Eagle's medium containing fetal calf serum. Confluent cultures are split the day before calcium phosphate cotransfection of plasmids.
- the cells are shocked (e.g., a 15% glycerol shock) to boost transfection efficiency and the cells are overlaid with agar in DMEM containing fetal calf serum, penicillin, streptomycin sulfate, and other antibiotics or antifungal agents as needed. Monolayers are incubated until viral plaques appear (about 5-15 days).
- shocked e.g., a 15% glycerol shock
- plaques are picked, suspended in medium containing fetal calf serum, and used to infect a new monolayer of 293 cells.
- viral lysates are subjected to a freeze/thaw cycle and designated as primary stocks.
- the presence of recombinant virus is verified by preparation of viral DNA from infected 293 cells, restriction analysis, and Southern blotting. Secondary stocks are subsequently generated by infecting 293 cells with primary virus stock at a multiplicity of infection of 0.01 and incubation until lysis.
- Recombinant adenovirus vectors can be propagated on, e.g., human 293 cells, or in other cell lines that are permissive for conditional replication-defective adenovirus infection, e.g., those which express adenovirus E1 gene products "in trans" so as to complement the defect in a conditional replication-defective vector. Further, the cells can be propagated either on plastic dishes or in suspension culture, to obtain virus stocks thereof.
- a coding sequence can comprise introns and exons so long as the coding sequence comprises at least one open reading frame for transcription, translation and expression of that polypeptide.
- a coding sequence can comprise a gene, a split gene or a cDNA molecule.
- the coding sequence comprises a split gene (contains one or more introns)
- a cell transformed or transfected with a DNA molecule containing that split gene must have means for removing those introns and splicing together the exons in the RNA transcript from that DNA molecule if expression of that gene product is desired.
- a coding sequence in an adenovirus vector can code for any dominant-negative cell cycle regulatory protein.
- the phrase "dominant negative cell cycle regulatory protein” means a protein that acts to inhibit cell proliferation or arrest cell growth at any of the cell cycle stages (e.g., S, GQ. or G- j ).
- Such dominant-negative cell cycle regulatory proteins are well known in the art. Exemplary and preferred such proteins are the p53 gene product, the p21 gene product and the retinoblastoma gene product (Rb).
- the classical tumor suppressor genes, p53 and Rb have each been shown to play important roles in regulating cell cycle progression in a number of mammalian cell types (Simons et al.. 1992; Morishita et AL 1993; Barr and Leiden. 1994; Hollingsworth et al.. 1993; Perrv and Levine. 1993; Helin and Harlow. 1993; Friend. 1994). Moreover, recent evidence suggests that p53-dependent G-i arrest of cell cycle progression is mediated at least in part through Rb or Rb-like proteins ( Slebos et al.. 1994).
- Rb or p53 either by mutation or by viral oncoproteins results in unregulated proliferation and tumorigenesis in both animals and humans (Lee et al.. 1988: Lee et al.. 1987; Friend et al., 1987; Williams et al.. 1994; Malkin et al.. 1990; Livingstone et al.. 1992: Donehower et al.. 1992).
- Rb plays a critical role in regulating the proliferation of vascular smooth muscle cells both in response to growth factor stimulation in vitro, and to injury in vivo and indicate significant parallels between the molecular mechanisms underlying carcinogenesis and those leading to human vascular proliferative disorders such as atherosclerosis and restenosis.
- in vivo gene transfer of dominant-negative cell cycle regulatory proteins into a number of different cell types are likely be useful for the treatment of a v -iety of human diseases associat ⁇ with uncontrolled cellular proliferation.
- the retinoblastoma gene product (Rb) is an important inhibitor of cell cycle progression in many mammalian cell types (Hollingsworth et aL. 1993; Perry and Levine. 1993; Helin and Harlow. 1993; Friend. 1994).
- Rb is unphosphorylated, and, in that state, binds to and inactivates a set of cellular transcription factors including E2F and Elf-1 that are important for cell cycle progression (Chen et al.. 1989; DeCaprio et al.. 1992; Kovesdi et al., 1986; Wang et al., 1993; Buchkovich et al.. 1989; Mihara ⁇ LaL.
- Rb becomes rapidly phosphorylated causing disruption of the Rb/E2F and Rb/Elf-1 complexes (Chen et al.. 1989; DeCaprio et al.. 1992; Kovesdi et aladmi 1986; Wang et al.. 1993; Buchkovich et al.. 1989; Mihara et al.. 1989: Bandara et al.. 1991: Huang et al.. 1991: Kaeline et al.. 1991).
- the release of these Rb-associated transcription factors is associated with progression through the G-
- Rb in regulating normal cell cycle progression has been underscored by the finding that mutations and deletions of Rb are associated with abnormal cell cycle progression and malignancies in both mice and humans (Lee et al.. 1988; Lee et al.. 1987; Friend et aL, 1987).
- Rb viral oncogenes including the SV40 large T antigen, adenovirus E1A and human papillomavirus E7 proteins bind to Rb, thereby competitively disrupting the Rb- transcription factor complexes and leading to unregulated cell proliferation
- the polynucleotide sequences of p21, p53 and Rb are well known in the art.
- a coding sequence of an adenovirus vector construct is preferably operatively linked to an enhancer-promoter other than an adenovirus enhancer-promoter.
- a promoter is a region of a DNA molecule typically within about 100 nucleotide pairs in front of (upstream of) the point at which transcription begins (i.e., a transcription start site). That region typically contains several types of DNA sequence elements that are located in similar relative positions in different genes.
- promoter includes what is referred to in the art as an upstream promoter region, a promoter region or a promoter of a generalized eukaryotic RNA Polymerase II transcription unit.
- An enhancer provides specificity of time, location and expression level for a particular encoding region (e.g., gene).
- a major function of an enhancer is to increase the level of transcription of a coding sequence in a cell that contains one or more transcription factors that bind to that enhancer.
- an enhancer can function when located at variable distances from transcription start sites so long as a promoter is present.
- the phrase "enhancer-promoter” means a composite unit that contains both enhancer and promoter elements.
- An enhancer-promoter is operatively linked to a coding sequence that encodes at least one gene product.
- the phrase "operatively linked” means that an enhancer-promoter is connected to a coding sequence in such a way that the transcription of that coding sequence is controlled and regulated by that enhancer-promoter.
- Means for operatively linking an enhancer-promoter to a coding sequence are well known in the art. As is also well known in the art, the precise orientation and location relative to a coding sequence whose transcription is controlled, is dependent inter alia upon the specific nature of the enhancer-promoter.
- a TATA box minimal promoter is typically located from about 25 to about 30 base pairs upstream of a transcription initiation site and an upstream promoter element is typically located from about 100 to about 200 base pairs upstream of a transcription initiation site.
- an enhancer can be located downstream from the initiation site and can be at a considerable distance from that site.
- An enhancer-promoter used in a vector construct of the present invention can be any enhancer-promoter that drives expression in a target cell.
- the human cytomegalovirus (CMV) immediate early gene promoter has been used to result in high-level expression of a gene.
- CMV human cytomegalovirus
- the use of other viral or mammalian cellular promoters which are well-known in the art is also suitable to achieve expression of the gene product provided that the levels of expression are sufficient to achieve a physiologic effect.
- enhancer-promoters are the CMV promoter, the Rous sarcoma virus (RSV) promoter, the EF1 ⁇ promoter, the muscle-specific creatine kinase (MCK) enhancer or the 4F2 heavy chain enhancer (Zambetti et al.. 1992; Yi et al.. 1991 and Sternberg et aL. 1988).
- an enhancer-promoter with well-known properties, the level and pattem of gene product expression can be optimized. For example, selection of an enhancer-promoter that is active specifically in vascular smooth muscle permits tissue-specific expression of the gene product.
- a vascular smooth muscle specific enhancer- promoter is an endothelin promoter (See e.g., Lee et al.. 1990 and Bloch et al.. 1989) or a smooth muscle -actin promoter (See e.g.,
- a coding sequence of an adenovirus vector construct is operatively linked to a transcription terminating region.
- RNA polymerase transcribes an encoding DNA sequence through a site where polyadenylation occurs.
- DNA sequences located a few hundred base pairs downstream of the polyadenylation site serve to terminate transcription.
- Those DNA sequences are referred to herein as transcription-termination regions. Those regions are required for efficient polyadenylation of transcribed messenger RNA (mRNA).
- a preferred transcription-terminating region used in an adenovirus vector construct of the present invention preferably comprises a polyadenylation signal of SV40 bovine growth hormone 3 or the protamine gene.
- Transducing is accomplished by delivering the expression vector to the cell or cells whose pathological proliferation is to be inhibited. Delivering is accomplished by infusing the vector into an artery that perfuses the target cell. In this way, delivery is localized to the target tissues.
- Targeted delivery of adenovirus vector containing a coding sequence for ⁇ -galactosidase ( ⁇ -gal) to cardiac muscle cells was accomplished by infusing that construct via a catheter placed into the left coronary artery or coronary sinus ostium (See Examples 1 , 2, and 5 hereinafter).
- Targeted delivery of adenovirus vector containing a coding sequence for Rb or p21to vascular smooth muscle cells was accomplished by infusing that construct via a catheter placed into an artery (See Examples 4 and 5 hereinafter).
- adenovirus vector employed in replication defective, it is not capable of replicating in the cells that are ultimately infected. Moreover, it has been found that the genomic integration frequency of adenovirus is usually fairly low. Thus, where continued treatment is required it may be necessary to reintroduce the virus every 6 months to a year. In these circumstances, it may therefore be necessary to conduct long term therapy, where expression levels are monitored at selected intervals.
- An adenovirus vector construct is typically delivered in the form of a pharmacological composition that comprises a physiologically acceptable carrier and the adenovirus vector construct.
- An effective expression-inducing amount of an adenovirus vector construct is delivered.
- the term "effective expression-inducing amount” means that number of virus vector particles necessary to effectuate expression of a gene product encoded by a coding sequence contained in that vector. Means for determining an effective expression-inducing amount of an adenovirus vector construct are well known in the art.
- An effective expression-inducing amount is typically from about 10 7 plaque forming units (pfu) to about 10 15 pfu, preferably from about 10 8 pfu to about 10 4 pfu and, more preferably, from about 10 9 to about 10 12 pfu.
- a specific dose level for any particular subject depends upon a variety of factors including the infectivity of the adenovirus vector, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, and the severity of the particular disease undergoing therapy.
- adenovirus is a virus that infects humans
- certain individuals that have developed antibodies to certain adenovirus proteins.
- an immunological reaction is believed to be a possibility
- Such a test can be performed in a variety of accepted manners, for example, through a simple skin test or through a test of the circulating blood levels of adenovirus-neutralizing antibodies.
- This example describes the use of recombinant replication defective adenoviruses in the preparation of virus vector constructs comprising a coding DNA sequence.
- adenovirus (Guzman et al.. 1982) containing distinct cDNAs (AdCMV-cDNA) were prepared in accordance with standard techniques well known in the art.
- E.coli ⁇ -galactosidase cDNA carrying the SV40 T antigen nuclear targeting signal (Bonnerot et al.. 1987) was inserted into pAdCMV to create a distinct construct comprising the cytomegalovirus (CMV) promoter, the ⁇ -Gal cDNA and a polyadenylation signal from either the SV40 virus or the mouse protamine gene, and flanked by adenovirus type 5 sequences.
- CMV cytomegalovirus
- E1 and E3 region of adenovirus were deleted and the E1 region was replaced by the ⁇ -Gal encoding sequence.
- AdCMV ⁇ -gal The resulting plasmid, designated AdCMV ⁇ -gal, was cotransfected into 293 cells. Co-transfection was performed as follows: 293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 2% fetal calf serum. Confluent dishes were split to non-confluent flasks the day before cotransfection with pAdCMV ⁇ -gal. Monolayers were incubated until the appearance of viral plaques.
- DMEM Dulbecco's modified Eagle's medium
- plaques were picked, suspended in DMEM containing 2% fetal calf serum and used to infect a new monolayer of 293 cells. When greater than 90% of the cells showed infection, viral lysates were subjected to a freeze/thaw cycle and were designated as primary stocks. Recombinant virus with the correct structure was verified by preparation of viral DNA from productively-infected 293 cells, restriction analysis, and Southern blotting. Secondary stocks were subsequently generated by infecting 293 cells with primary virus stock and incubation until lysis.
- the large scale production of recombinant adenovirus was performed in 293 cells. Infected cells were lysed 48 hours post- infection. Virus-containing extracts were centrifuged to remove debris before precipitation of the virus. Virus was collected by centrifugation, resuspended in isotonic medium, purified, and sterilized.
- CsCI 1 g/ml
- vascular smooth muscle cells were placed in serum free medium (50% DMEM, 50% Ham's F- 12, 292 mg/ml l-glutamine, 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml selenious acid) for 96 hours and then stimulated by incubation in 45% DMEM, 45% Ham's F-12, 10% FCS.
- Cell lysates were prepared as described previously (Chen et al.. 1989: DeCaprio et al.. 1992; JSQYS ⁇ LaL, 1986; Wang et al.. 1993; Buchkovich et al.. 1989; Mihara et al..
- AdEFIHA ⁇ Rb a replication-defective adenovirus vector, AdEFIHA ⁇ Rb, that encodes a non- phosphorylatable, constitutively active form of human Rb (hRb) containing a 10 amino acid N-terminal epitope tag from the influenza hemagglutinin molecule (HA).
- HA influenza hemagglutinin molecule
- This mutant form of Rb (HA ⁇ Rb) has been reported previously to inhibit E2F- and E If- 1 -dependent transcription in P19 (Hamel et al.. 1992) and T cells (Chen et al.. 1989; DeCa p rio et al.. 1992; Kovesdi et al., 1986; Wang et al.. 1993; Buchkovich et al.. 1989; Mihara et al.. 1989;
- AdBAc.lacZ a replication-defective adenovirus containing the bacterial lacZ gene under the control of the chicken ⁇ -actin promoter and cytomegalovirus enhancer (Kozarsky et aL 1993).
- quiescent rat aortic smooth muscle cells were infected with 20 pfu/cell of AdEFIHA ⁇ Rb and then stimulated to proliferate by incubation in 10% FCS.
- Control cultures were infected with Ad ⁇ Ac.lacZ or were left uninfected prior to serum stimulation.
- Serum stimulation caused the rapid proliferation of the uninfected or Ad ⁇ Ac.lacZ- infected vascular smooth muscle cells. During the first 48 hours after stimulation, these cells underwent approximately 3 doublings.
- infection with AdEFIHA ⁇ Rb caused a greater than 90% reduction in smooth muscle cell proliferation.
- Ad ⁇ Ac.lacZ and AdEFIHA ⁇ Rb- infected cells were more than 97% viable at the end of the experiment as determined by trypan blue exclusion.
- the lack of proliferation seen following AdEFIHA ⁇ Rb infection represented cell cycle arrest as opposed to cell killing in these experiments.
- Rb has been shown to block cell cycle progression at the G- j /S transition (Goodrich et aL 1991).
- AdEFHA ⁇ Rb-infected vascular smooth muscle cells were arrested prior to the S phase of the cell cycle, 3 Hthymidine incorporation was measured in these cells following serum stimulation. Serum stimulation of both the uninfected and Ad ⁇ Ac.lacZ- infected vascular smooth muscle cells was associated with significant increases in 3 H- thymidine incorporation during the first 24 to 48 hours after stimulation.
- the rat carotid artery injury model represents a well characterized, reproducible vascular proliferative disorder that is dependent on smooth muscle cell migration and proliferation (Simons et al.. 1992; Morishita et aL 1993; Barr and Leiden. 1994; Clowes and Reidy. 1983).
- Balloon angioplasty of the porcine femoral artery produces a neointimal lesion that has been used as a model of human vascular proliferative disease.
- both the size and structural organization of this vessel closely resemble those of the human coronary arteries (Prescott et aL 1991: Reitman et al.. 1982; Weiner et aL, 1985: Ohno et al.. 1994).
- RNA and a commercially available kit Perkin Elmer, Norwalk, CT
- reverse transcriptase reverse transcriptase
- PCR was performed as described previously (Barr et aL 1994) using primers specific for the HA ⁇ Rb cDNA [AAGCTTCCCGGGG AATTCACC ATGGGGTACCCATACG ATGTTCCAG ATTACG (sense)(SEQ ID NO:1) and
- ATAGCATTATCAACCTTGGTACTGG (antisense)(SEQ ID NO:2)] or the mouse ⁇ -actin cDNA [GTGACGAGGCCCAGAGCAAGAG (sense)(SEQ ID NO:3) and AGGGGCCGGACTCATCGTACTC (antisense)(SEQ ID NO:4)].
- Southern blot analysis was performed using a radiolabeled probe corresponding to bp 1 to 392 of the HA ⁇ Rb cDNA (Barr et al.. 1994).
- HA ⁇ Rb RNA was detected in the AdEFIHA ⁇ Rb-infected but not in the control AdBglll-infected or contralateral uninfected carotid arteries.
- rat carotid arteries were subjected to balloon angioplasty and immediately infected with either 2 X 10 9 pfu of AdEF1 HA ⁇ Rb or a control AdBglll virus.
- a third set of arteries was treated with vehicle (HEPES-buffered saline) alone.
- Two assays were used to measure smooth muscle cell proliferation in vivo.
- AdEFIHA ⁇ Rb- infected and control arteries were stained for 5'-bromodeoxyuridine (BrdU) (Simons et aL 1992; Morishita et al..
- Carotid arteries of adult rats were injured by balloon angioplasty. Immediately following balloon injury, arteries were infected with 2 X 1p 9 pfu of either AdBglll or AdEFIHA ⁇ Rb, or were left uninfected. Animals received subcutaneous injections of 25 mg/kg of 5'- bromodeoxyuridine at 12 hour intervals starting 24 hours following injury for a total of 4 doses. Carotid arteries were fixed in situ by intravascular administration of 4% paraformaldehyde, paraffin- embedded, and sectioned.
- Deparaffinized 5 mm sections were treated with 3% H 2 ⁇ 2 in methanol and permeabilized by incubation in 0.4% pepsin and 3.3 M HCI. Treated sections were blocked in 1.5% horse serum, incubated with a 1:100 dilution of an -BrdU mAb (Becton- Dickinson, San Jose, CA). The sections were then incubated with a 1:200 dilution of biotinylated horse -mouse Ig antiserum, followed by avidin-conjugated horseradish peroxidase (Vectastain Elite ABC kit, Vector laboratories, Burlingame, CA). Sections were then treated with diaminobenzidine (DAB) and counterstained with Hematoxylin and Eosin. Statistical analyses were performed using Sigmaplot (Jandel Scientific, Corte Madera, CA).
- Neointimal and medial boundaries were determined by digital planimetry of tissue sections using the MOCHA program (Jandel Scientific, Corte Madera, CA) on a Gateway 486 computer. The neointimal and medial cross-sectional areas were measured from six sections of each artery and the mean of these six determinations was used to calculate the neointimal to medial cross-sectional ratio for each animal.
- Uninfected and control AdBglll-infected arteries had l/M area ratios of 1.4 0.1 and 1.2 0.1 , respectively.
- the AdEF1 HA ⁇ Rb-infected arteries demonstrated a 42% reduction in the l/M ratio as compared to the AdBglll-infected controls and a 50% reduction as compared to uninfected control arteries.
- overexpression of HA ⁇ Rb following adenovirus-mediated in vivo gene transfer at the time of injury resulted in significant reductions in both vascular smooth muscle cell proliferation and restenosis in the rat carotid artery model of balloon angioplasty.
- arteries harvested 20 days after injury were stained with an -von Willebrand Factor mAb (Hruban et al.. 1987).
- Rat carotid arteries were harvested 21 days after balloon injury and infection with AdEFIHA ⁇ Rb and embedded in paraffin.
- 5 mm sections were stained with a commercially available -vWF mAb (Dako, Santa Barbara, CA) (Hruban et al.. 1987) followed by a biotinylated goat anti-mouse IgG using an automatic immunostainer (Ventana Immunosystems, Arlington, AZ).
- Slides were developed with avidin- conjugated alkaline phosphatase and fast red-naphthol (Ventana Immunosystems) according to the manufacturer's instructions.
- AdEF1 HA ⁇ Rb-infected arteries demonstrated a 47% reduction in the l/M area ratio as compared to the AdBglll-infected controls.
- AdEF1 HA ⁇ Rb infection significantly reduces neointimal formation in two different animal models of restenosis.
- AdEFIHA ⁇ Rb infection did not result in increased vascular inflammation or cell necrosis as compared to vehicle-treated or AdBglll- treated control arteries.
- routine serum chemistries including electrolytes, liver function tests, complete blood counts, and clotting parameters were ail normal in rats 21 days following intra-arterial infusions of AdEFIHA ⁇ Rb.
- Pigs receiving AdEFIHA ⁇ Rb demonstrated a mild reduction in serum phosphate as compared to saline control- treated animals. The mechanism of this reduction remains unclear.
- HSV TK Herpes Simplex Virus thymidine kinase
- cytostatic therapy using Rb gene transfer has the advantage of arresting cell cycle progression without causing cell necrosis or inflammation in the vessel wall.
- adenovirus-mediated gene transfer can be performed using percutaneous catheter-based techniques. The data further demonstrate the safety, efficacy and feasibility of this approach in two different animal models of restenosis.
- Adp2l and AdlacZ are E1- and E3-deleted replication-defective adenovirus vectors derived from Ad5 sub360.
- Adp21 encodes the human p21 cDNA under the transcriptional control of the human elongation factor-1 ⁇ (EF1 ⁇ ) gene promoter and the human 4F2 heavy chain gene transcriptional enhancer.
- AdlacZ contains the bacterial lacZ gene under the transcriptional control of the chicken ⁇ -actin gene promoter and the cytomegalovirus transcriptional enhancer. Both viruses were prepared and grown as high titer stocks in 293 cells. All virus stocks were purified by centrifugation in discontinuous CsCI gradients and dialyzed against a Hepes-buffered saline solution.
- VSMCs Isolation and infection of primary rat aortic VSMCs were performed as described in Example 1. For measurements of cell proliferation, DNA synthesis, and cell cycle analysis passage 3, VSMCs were incubated in serum-free medium for 48 hours prior to infection with either Adp21 or AdlacZ. This protocol resulted in 70- 90% of the cultured cells accumulating in GO + G1 of the cell cycle as assessed by propidium iodide staining and FACS analysis.
- Adp21- or AdlacZ-infected cells were stimulated to proliferate by incubation in growth medium (45% DMEM, 45% Hams F-12, and 10% FBS) (GibcoBRL, Grand Island, NY).
- VSMCs were pulse-labeled for 4 hours in growth medium containing methyl-3H thymidine (1uCi/ml, 2 Ci/mmol; Amersham, Arlington Heights, IL). Each experiment was performed in triplicate in 6- we 11 tissue culture plates (Falcon, Franklin Lakes, NJ).
- Adp21- infected VSMCs expressed markedly elevated levels of p21 as compared to both uninfected and AdlacZ-infected control cells. High levels of p21 expression were observed within 24 hours of infection and the levels of p21 expression increased further between 24 and 48 hours after infection. Of note, in some experiments, both uninfected and AdlacZ-infected cell lysates displayed low levels of expression of a 21 kD protein that co-migrated with in vitro translated human p21.
- AdlacZ-infected cells proliferated rapidly during the first 48 hours following serum stimulation, undergoing approximately two doublings. In contrast, infection with Adp21 resulted in dose-dependent reductions in VSMC proliferation. At both the 24 and 48 hour time points, each of the Adp21 -infected cell cultures (10, 20 and 40 PFU per cell) demonstrated significantly less proliferation than the control AdlacZ-infected cells (P ⁇ 0.02).
- VSMCs were fixed overnight at 4%C with 75% ethanol and stained for 30 minutes at room temperature with propidium iodide (50 mg/ml). Cells were analyzed with a Becton Dickinson FACScan and
- p21 can bind to and inhibit the activity of the DNA polymerase cofactor, PCNA. Inhibition of PCNA-dependent DNA synthesis may therefore reflect a second mechanism by which p21 inhibits cell cycle progression.
- PCNA DNA polymerase cofactor
- Recent studies have demonstrated that different regions of the p21 protein are involved in binding to CDKs and PCNA thereby suggesting that p21 may inhibit cell cycle progression by at least two distinct molecular mechanisms.
- quiescent rat aortic VSMCs were infected with 40 PFU per cell of Adp21 or AdlacZ and then stimulated to proliferate for 24 hours by incubation in medium containing 10% FCS. Lysates prepared from these infected cells were immunoprecipitated with an -p21 antibody and the immunoprecipitates subjected to immunoblot analyses with either -p21 or -PCNA antibodies.
- p21 was immunoprecipitated from the Adp21 -infected but not from the AdlacZ- infected VSMCs. More importantly, PCNA was co-immunoprecipitated with p21 from Adp21 -infected but not from AdlacZ-infected VSMC lysates. Thus, p21 forms complexes with PCNA following Adp21 infection of VSMCs.
- the rat carotid artery balloon injury model represents a well- characterized, highly reproducible vascular proliferative disorder that is dependent on VSMC proliferation and migration. Previous studies using this model have demonstrated that medial VSMC proliferation begins within 2 days of arterial injury, reaching a peak within 4 days. By 20 days after balloon angioplasty, nearly all of the injured arteries develop a stable neointimal lesion and demonstrate no evidence of VSMC proliferation in either the neointima or the media of the vessel wall.
- rat carotid arteries were subjected to balloon angioplasty and immediately infected with 2 X 10 9 PFU of either
- Adp21 or AdlacZ This protocol results in the transduction of more than 70% of the medial VSMC in the injured arterial segment.
- injured arterial segments were harvested 4 days after infection and crude lysates prepared from these arteries were assayed for p21 expression by immunoblot analysis.
- cell lysates were prepared and 100 ⁇ g total protein from each sample was fractionated by SDS-PAGE in 15% gels and subjected to immunoblot analysis using a rabbit polyclonal -p21 antibody (Pharmingen, San Diego, CA) (1:1000 dilution).
- a peroxidase-labeled, goat -rabbit antiserum (1:3000 dilution) (GibcoBRL) was used in conjunction with the ECL chemiluminescence system (Amersham) for detection of bound primary antibody.
- the beads were washed 3 times with Tween lysis buffer and the immunoprecipitated proteins were released by boiling in SDS-PAGE loading buffer, fractionated by electrophoresis in 15% denaturing SDS polyacrylamide gels and subjected to immunoblot analyses using a polyclonal rabbit - p21 antibody (1:1000 dilution) (Pharmingen) or a mouse -PCNA mAb (1:100 dilution) (Santa Cruz, Santa Cruz, CA) as described above.
- passage 3 VSMCs cells were incubated in serum free medium for 96 hours, infected with adenovirus as described above and, 24 hours after infection, were stimulated to proliferate by incubation in growth medium.
- Cell lysates were prepared and protein corresponding to 5 X 10 5 cells from each sample was fractionated by electrophoresis in 7.5% SDS polyacrylamide gels and subjected to immunoblot analysis using an -Rb monoclonal antibody (1:200 dilution) (Pharmingen) and a peroxidase-labeled, goat -mouse IgG antiserum (1 :2000 dilution) (Gibco/BRL) in conjunction with ECL chemiluminescence system (Amersham).
- Rat carotid arteries were harvested 20 days after balloon injury and adenovirus infection. 5 ⁇ m sections from paraffin-embedded arteries were stained with hematoxylin and eosin and the neointimal and medial boundaries were determined on coded slides by an investigator blinded to the experimental conditions. Areas and ratios were determined by digital planimetry of tissue sections using the
- Image Pro-Plus image analysis system (Fryer Co, Chicago, IL). The l/M ratios were measured from 6 sections of each artery subjected to balloon angioplasty and adenovirus infection. The mean of these determinations was used to calculate the l/M cross-sectional ratios for each animal.
- Coronary artery disease (CAD) due to atherosclerosis is the leading cause of morbidity and mortality in the United States.
- PTCA remains a mainstay of therapy for symptomatic CAD, with more than 400,000 procedures expected in 1995 in the United States alone. While the procedure is initially successful in relieving arterial stenoses in the vast majority of patients, clinically significant restenosis continues to complicate the procedure in up to 40% of cases.
- HSV-tk herpes simplex virus thymidine kinase gene
- Biopolymer-mediated delivery of antisense oligonucleotides directed to c-myb or PCNA and cdc2 have also both been reported to inhibit neointimal hyperplasia in the rat carotid artery injury model.
- antisense oligonucleotides may cause degradation of multiple RNA species and have important non-specific effects on intracellular and cell surface proteins.
- antisense oligonucleotides may be subject to significant batch-to-batch variability and to date it is been impossible to efficiently deliver antisense oligonucleotides to the vascular wall using non-viral, catheter mediated approaches.
- adenovirus mediated over-expression of a non-phosphorylatable constitutively active form of Rb has also been shown to significantly reduce restenosis in both the rat carotid and pig iliofemoral artery models of balloon angioplasty.
- a cytostatic gene therapy approach using catheter-mediated delivery of Adp21 as described herein is a clinically applicable, effective and non-toxic treatment for vascular proliferative disorders.
- the degree of inhibition of restenosis achieved by Adp21 gene transfer in the present studies (46%) was comparable to that achieved with over-expression of HA ⁇ Rb, as well as with HSV-tk gene transfer with systemic ganciclovir therapy, and the intraluminal delivery of antisense oligonucleotides.
- administration of Adp21 was not associated with significant inflammatory responses and clinical toxicity in the present study.
- Adp21 appears to inhibit two proliferative pathways (cyclin/CDKs and PCNA) makes it a more potent cytostatic agent than AdHA ⁇ Rb.
- the more pleiotropic activities of Adp21 may result in more undesirable side effects in vivo.
- Co-administration of Adp21 and AdHA ⁇ Rb can be more efficacious than the administration of either virus alone.
- cyclin/CDK kinases are important regulators of proliferation in a wide variety of cell types, adenovirus mediated over-expression of p21 is likely useful for the treatment of other human diseases associated with deregulated cell proliferation.
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention se rapporte à la mise en oeuvre d'un transfert de gène afin d'inhiber la prolifération cellulaire pathologique non néoplasique. Le procédé consiste à administrer à une cellule proliférative un vecteur d'expression eucaryotique comprenant une séquence polynucléotidique codant pour une protéine de régulation négative dominante du cycle cellulaire. L'administration est réalisée par injection d'un vecteur d'expression dans une artère qui irrigue ou renferme la cellule proliférative.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45020/96A AU4502096A (en) | 1994-11-11 | 1995-11-13 | A process of inhibiting non-neoplastic pathological cell proliferation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33837294A | 1994-11-11 | 1994-11-11 | |
US08/338,372 | 1994-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996015245A1 true WO1996015245A1 (fr) | 1996-05-23 |
Family
ID=23324561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/015191 WO1996015245A1 (fr) | 1994-11-11 | 1995-11-13 | Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4502096A (fr) |
WO (1) | WO1996015245A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025507A3 (fr) * | 1995-02-17 | 1996-11-07 | Us Health | Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines |
WO1996027008A3 (fr) * | 1995-02-28 | 1996-11-14 | Max Planck Gesellschaft | Agent utilise dans le traitement de tumeurs et d'autres hyperplasies |
WO1998037190A1 (fr) * | 1997-02-20 | 1998-08-27 | Hepavec Aktiengesellschaft Für Gentherapie | METHODE PERMETTANT DE PROVOQUER UNE MORT CELLULAIRE PROGRAMMEE DANS DES CELLULES MALIGNES PAR REDUCTION DU RAPPORT PROTEINES Rb/PROTEINES INDUISANT L'APOPTOSE |
WO2000039293A3 (fr) * | 1998-12-23 | 2000-11-09 | Max Delbrueck Centrum | Agent inhibant la neoformation tissulaire |
JP2007504274A (ja) * | 2003-05-10 | 2007-03-01 | ペン、ジャオフイ | 増殖性疾患を治療するためのアデノウイルスベクターとp53遺伝子との組換え体遺伝子医薬 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009114A1 (fr) * | 1989-12-07 | 1991-06-27 | Research Development Foundation | Regulation dependant du cycle de cellule de phosphorylation d'un produit genetique de retinoblastome humain |
WO1991015580A1 (fr) * | 1990-04-10 | 1991-10-17 | Research Development Foundation | Therapie genetique contre des maladies proliferatives cellulaires |
WO1993012251A1 (fr) * | 1991-12-16 | 1993-06-24 | Baylor College Of Medicine | Inhibiteurs de synthese d'adn derives des cellules senescentes |
WO1994011506A1 (fr) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Transfert de genes au moyen d'un adenovirus au muscle lisse cardiaque et vasculaire |
-
1995
- 1995-11-13 AU AU45020/96A patent/AU4502096A/en not_active Abandoned
- 1995-11-13 WO PCT/US1995/015191 patent/WO1996015245A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009114A1 (fr) * | 1989-12-07 | 1991-06-27 | Research Development Foundation | Regulation dependant du cycle de cellule de phosphorylation d'un produit genetique de retinoblastome humain |
WO1991015580A1 (fr) * | 1990-04-10 | 1991-10-17 | Research Development Foundation | Therapie genetique contre des maladies proliferatives cellulaires |
WO1993012251A1 (fr) * | 1991-12-16 | 1993-06-24 | Baylor College Of Medicine | Inhibiteurs de synthese d'adn derives des cellules senescentes |
WO1994011506A1 (fr) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Transfert de genes au moyen d'un adenovirus au muscle lisse cardiaque et vasculaire |
Non-Patent Citations (12)
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025507A3 (fr) * | 1995-02-17 | 1996-11-07 | Us Health | Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines |
WO1996027008A3 (fr) * | 1995-02-28 | 1996-11-14 | Max Planck Gesellschaft | Agent utilise dans le traitement de tumeurs et d'autres hyperplasies |
WO1998037190A1 (fr) * | 1997-02-20 | 1998-08-27 | Hepavec Aktiengesellschaft Für Gentherapie | METHODE PERMETTANT DE PROVOQUER UNE MORT CELLULAIRE PROGRAMMEE DANS DES CELLULES MALIGNES PAR REDUCTION DU RAPPORT PROTEINES Rb/PROTEINES INDUISANT L'APOPTOSE |
WO2000039293A3 (fr) * | 1998-12-23 | 2000-11-09 | Max Delbrueck Centrum | Agent inhibant la neoformation tissulaire |
JP2007504274A (ja) * | 2003-05-10 | 2007-03-01 | ペン、ジャオフイ | 増殖性疾患を治療するためのアデノウイルスベクターとp53遺伝子との組換え体遺伝子医薬 |
JP4695086B2 (ja) * | 2003-05-10 | 2011-06-08 | ペン、ジャオフイ | 増殖性疾患を治療するためのアデノウイルスベクターとp53遺伝子との組換え体遺伝子医薬 |
Also Published As
Publication number | Publication date |
---|---|
AU4502096A (en) | 1996-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6436907B1 (en) | Adenovirus-medicated gene transfer to cardiac and vascular smooth muscle | |
Smith et al. | p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. | |
CA2174556C (fr) | Procedes et compositions relatifs a l'adenovirus p53 recombine | |
US8329671B2 (en) | Reduction of dermal scarring | |
US6503498B1 (en) | Apolipoprotein A-1 adenovirus vector compositions and methods | |
WO1996015245A1 (fr) | Procede d'inhibition de la proliferation cellulaire pathologique non neoplasique | |
US6902731B1 (en) | Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins | |
US6200799B1 (en) | Somatic gene therapy to suppress secondary cataract formation following eye surgery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |